Table 3. Pre-incubation neutralization assay using 3BC176 and 3BC315.
|
JR-FL | ||||||
|---|---|---|---|---|---|---|
| Pre-incubation (h) | IC50 (μg ml−1) | Fold change | IC50 (μg ml−1) | Fold change | IC50 (μg ml−1) | Fold change |
|
3BC176 |
3BC315 |
35O22 |
||||
| 1 | 0.30 | 5.84 | 0.0023 | |||
| 3 | 0.16 | 1.8 | 3.69 | 1.6 | 0.0028 | 0.8 |
| 6 | 0.11 | 2.7 | 2.34 | 2.5 | 0.0012 | 2.0 |
| 22 | 0.03 | 8.7 | 0.83 | 7.0 | 0.0015 | 1.5 |
|
sCD4 |
PGT145 |
2G12 |
||||
| 1 | 0.61 | 0.0064 | 0.12 | |||
| 3 | 0.33 | 1.8 | 0.0048 | 1.3 | 0.11 | 1.1 |
| 6 | 0.28 | 2.2 | 0.0041 | 1.5 | 0.13 | 1.0 |
| 22 | 0.13 | 4.9 | 0.0019 | 3.3 | 0.09 | 1.4 |
|
D5 |
T-20 |
|||||
| 1 | 1,045 | 0.019 | ||||
| 3 | 722 | 1.4 | 0.022 | 0.9 | ||
| 6 | 1,290 | 0.8 | 0.017 | 1.1 | ||
| 22 | 686 | 1.5 | 0.016 | 1.2 | ||
|
BG505 | ||||||
|
3BC176 |
3BC315 |
35O22 |
||||
| 1 | 1.93 | 1.62 | 0.0022 | |||
| 3 | 1.04 | 1.9 | 1.01 | 1.6 | 0.0011 | 2.1 |
| 6 | 0.82 | 2.4 | 0.71 | 2.3 | 0.0014 | 1.6 |
| 22 | 0.33 | 5.8 | 0.41 | 4.0 | 0.0011 | 2.0 |
|
sCD4 |
PGT145 |
2G12 |
||||
| 1 | 3.05 | 0.0096 | 0.092 | |||
| 3 | 2.74 | 1.1 | 0.0085 | 1.1 | 0.099 | 0.9 |
| 6 | 2.42 | 1.3 | 0.0099 | 1.0 | 0.101 | 0.9 |
| 22 | 1.19 | 2.6 | 0.0069 | 1.4 | 0.064 | 1.4 |
|
D5 |
T-20 |
|||||
| 1 | 125 | 1.17 | ||||
| 3 | 110 | 1.1 | 1.03 | 1.1 | ||
| 6 | 161 | 0.8 | 0.95 | 1.2 | ||
| 22 | 130 | 1.0 | 1.14 | 1.0 | ||
JR-FL or BG505 virus was incubated with antibody for various times, before adding to TZM-bl cells to test for infectivity. IC50 values of 3BC315 and 3BC176 decrease as the antibody is pre-incubated with the viruses for longer times, indicating that these antibodies neutralize by inactivating Env over time. Fold change (decrease) in IC50 is calculated relative to the standard 1h incubation time. Incubations resulting in a >3-fold change are shown in boldface.